[HTML][HTML] Induction of CD8+ T-cell responses against novel glioma–associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic …

H Okada, P Kalinski, R Ueda, A Hoji… - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
H Okada, P Kalinski, R Ueda, A Hoji, G Kohanbash, TE Donegan, AH Mintz, JA Engh…
Journal of clinical oncology, 2011ncbi.nlm.nih.gov
Purpose A phase I/II trial was performed to evaluate the safety and immunogenicity of a
novel vaccination with α-type 1 polarized dendritic cells (αDC1) loaded with synthetic
peptides for glioma-associated antigen (GAA) epitopes and administration of polyinosinic-
polycytidylic acid [poly (I: C)] stabilized by lysine and carboxymethylcellulose (poly-ICLC) in
HLA-A2+ patients with recurrent malignant gliomas. GAAs for these peptides are EphA2,
interleukin (IL)-13 receptor-α2, YKL-40, and gp100.
Abstract
Purpose
A phase I/II trial was performed to evaluate the safety and immunogenicity of a novel vaccination with α-type 1 polarized dendritic cells (αDC1) loaded with synthetic peptides for glioma-associated antigen (GAA) epitopes and administration of polyinosinic-polycytidylic acid [poly (I: C)] stabilized by lysine and carboxymethylcellulose (poly-ICLC) in HLA-A2+ patients with recurrent malignant gliomas. GAAs for these peptides are EphA2, interleukin (IL)-13 receptor-α2, YKL-40, and gp100.
ncbi.nlm.nih.gov